GLP-1 Treatments
Updated April 2026

Ozempic vs Bariatric Surgery:
Which Is Right for You?

A comprehensive UK comparison of GLP-1 medication and weight loss surgery — effectiveness, costs, risks, and how to decide which path suits your situation.

Key points

  • Bariatric surgery produces 20–35% total body weight loss; semaglutide achieves approximately 15% on average
  • Surgery is irreversible with a 2–5% serious complication rate; GLP-1 therapy is reversible with mainly gastrointestinal side effects
  • NHS-funded surgery requires BMI ≥40 (or ≥35 with comorbidities) and Tier 3 pathway completion; private surgery costs £8,000–£15,000
  • Private semaglutide costs approximately £200–£300 per month; NHS access is expanding under NICE 2026 guidance
  • A combination approach — GLP-1 before or after surgery — is gaining clinical support

Understanding the two approaches

The treatment landscape for obesity in the United Kingdom has changed dramatically. For decades, bariatric surgery was the only intervention shown to produce substantial, sustained weight loss. The arrival of GLP-1 receptor agonists — particularly semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) — has created a genuine alternative for many patients.

Both approaches work, but they suit different clinical situations. This guide examines the evidence for each so you can have an informed conversation with your healthcare team about the best path forward.

Weight loss effectiveness: head-to-head

The most common question patients ask is straightforward: which works better? The answer depends on how you define success and which procedure or dose is being compared.

Treatment Average weight loss Timeframe Key trial
Semaglutide 2.4 mg (Wegovy) 15–17% 68 weeks STEP 1
Tirzepatide 15 mg (Mounjaro) 20–22% 72 weeks SURMOUNT-1
Gastric sleeve 25–30% 12–18 months Multiple RCTs
Gastric bypass (Roux-en-Y) 30–35% 12–18 months Multiple RCTs
Gastric band 15–20% 12–24 months Multiple RCTs

Bariatric surgery — particularly sleeve gastrectomy and Roux-en-Y gastric bypass — remains the most effective single intervention for weight loss. However, the gap is narrowing, especially with newer dual-agonist medications like tirzepatide, and next-generation triple agonists in clinical trials.

Important context: The STEP 1 and SURMOUNT trials enrolled patients with a mean BMI of approximately 37. Bariatric surgery studies typically include patients with higher baseline BMIs (40+), where absolute weight loss tends to be greater. Direct comparison should be interpreted cautiously.

How each treatment works

GLP-1 medications

Semaglutide mimics the natural gut hormone GLP-1, acting on receptors in the brain to reduce appetite, slow gastric emptying and improve satiety signalling. The medication is administered as a weekly subcutaneous injection. Weight loss occurs gradually and depends on continued use — stopping the medication typically leads to weight regain.

Bariatric surgery

Surgery physically alters the digestive tract. A gastric sleeve removes approximately 80 per cent of the stomach, while gastric bypass creates a small stomach pouch and reroutes the intestine. These changes reduce food capacity, alter gut hormone production (including GLP-1 itself), and permanently modify digestive physiology.

NHS pathway and eligibility

GLP-1 medications on the NHS

Under current NICE guidelines (updated 2025–2026), Wegovy is available on the NHS for adults with a BMI of 35 or above (or 30+ with weight-related comorbidities) who have been through a Tier 3 specialist weight management service. Mounjaro received NICE approval for weight management in early 2026, broadening the options available.

In practice, access varies significantly by region. Some integrated care boards (ICBs) have implemented GLP-1 prescribing; others face supply constraints or commissioning delays.

Bariatric surgery on the NHS

NHS-funded bariatric surgery requires completion of the Tier 3 weight management pathway (typically 12–24 months), a BMI of 40 or above (or 35+ with significant comorbidities such as type 2 diabetes or obstructive sleep apnoea), and demonstration that non-surgical approaches have been unsuccessful.

Waiting times for NHS bariatric surgery are substantial. According to NHS data, the median wait from referral to surgery exceeds 2 years in many trusts, with some patients waiting 3 years or longer. This delay has made GLP-1 medications an attractive interim or alternative option.

Costs: NHS vs private

Option NHS cost to patient Private cost
Semaglutide (Wegovy) Free (if eligible) £200–£300/month
Tirzepatide (Mounjaro) Free (if eligible) £200–£350/month
Gastric sleeve Free (if eligible) £8,000–£10,000
Gastric bypass Free (if eligible) £10,000–£15,000
Gastric band Free (if eligible) £5,000–£8,000

An important financial consideration: GLP-1 medication is an ongoing expense. At £250 per month privately, the annual cost is £3,000. Over five years, that totals £15,000 — comparable to the one-off cost of surgery. If long-term or lifelong medication is required (as current evidence suggests), surgery may be more cost-effective for patients who require sustained, significant weight loss.

Risks and side effects

GLP-1 medication risks

Bariatric surgery risks

Important: Bariatric surgery requires lifelong nutritional supplementation (multivitamins, iron, B12, calcium and vitamin D) and annual blood monitoring. Failure to maintain supplementation can lead to serious deficiency-related health problems.

Weight regain: the long-term picture

Weight regain is a reality with both approaches, though the patterns differ significantly.

The STEP 1 extension trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. This has led most clinicians to view GLP-1 therapy as a long-term or indefinite treatment, much like medications for hypertension or diabetes.

After bariatric surgery, weight regain of 10–25 per cent of maximum weight lost is common at the 5-year mark, with greater regain observed after 10 years. However, most patients maintain a significantly lower weight than their pre-surgical baseline. Approximately 20–30 per cent of surgical patients experience clinically significant weight regain.

For patients who regain weight after stopping GLP-1 medication or after surgery, a combination approach is increasingly considered.

The combination approach

Rather than viewing medication and surgery as competing options, a growing body of evidence supports using them together.

GLP-1 before surgery (preoperative)

Several UK bariatric centres now prescribe semaglutide or liraglutide for 2–4 weeks before surgery. This reduces liver volume (which is often enlarged in obesity), making laparoscopic surgery safer and technically easier. Preoperative weight loss also reduces surgical complication rates.

GLP-1 after surgery (postoperative)

For patients who experience weight regain following bariatric surgery, GLP-1 medications can provide an additional 10–15 per cent weight loss from the regained weight. Early evidence from retrospective studies supports this approach, and prospective trials are underway. This represents a genuinely new treatment paradigm rather than a choice between one option and the other.

Who should consider which option?

GLP-1 medication may be better suited if:

Your BMI is between 30 and 40, you prefer a non-surgical approach, you have concerns about surgical risks, you want to assess your response before committing to a permanent change, or you have contraindications to general anaesthesia.

Bariatric surgery may be better suited if:

Your BMI is above 40 (or 35+ with serious comorbidities), you have tried medication without sufficient results, you have type 2 diabetes that would benefit from the metabolic effects of surgery, you prefer a one-off procedure over indefinite medication, or you need the greatest possible weight loss.

Making the decision: questions to discuss with your doctor

  1. What is my current BMI and do I have weight-related comorbidities that influence eligibility?
  2. Am I eligible for NHS-funded treatment (medication or surgery)?
  3. What are the waiting times in my area for each pathway?
  4. Am I prepared for long-term or lifelong medication if I choose the GLP-1 route?
  5. Am I fit for general anaesthesia and abdominal surgery?
  6. Have I completed or am I willing to complete a Tier 3 weight management programme?
  7. Could a combined approach (medication before, during or after surgery) be appropriate for me?

The future of obesity treatment in the UK

The field is evolving rapidly. Next-generation medications — including triple agonists such as retatrutide (GLP-1/GIP/glucagon) — are showing weight loss results of 24–28 per cent in clinical trials, approaching and potentially matching surgical outcomes. If these compounds receive MHRA and NICE approval, the decision framework may shift further towards pharmacotherapy as a first-line option.

Meanwhile, surgical techniques continue to improve, with endoscopic procedures (such as endoscopic sleeve gastroplasty) offering less invasive alternatives with lower complication rates, albeit with somewhat lower weight loss efficacy.

For now, the best approach is the one tailored to your individual circumstances, discussed in detail with a specialist in obesity medicine or bariatric surgery.

Frequently asked questions

Is Ozempic as effective as bariatric surgery for weight loss?
Bariatric surgery generally produces greater total weight loss (20 to 35 per cent of body weight) compared with semaglutide (approximately 15 per cent). However, semaglutide avoids the surgical risks, recovery time and irreversibility of surgery. For many patients with a BMI of 30 to 40, GLP-1 therapy achieves clinically meaningful results without an operation.
Can I try Ozempic before bariatric surgery?
Yes. Many NHS Tier 3 weight management services now offer GLP-1 medications as a step before considering surgery. Some surgeons also prescribe semaglutide preoperatively to reduce liver volume and surgical risk. A medication-first approach allows you to assess your response before committing to an irreversible procedure.
How much does bariatric surgery cost privately in the UK?
Private bariatric surgery in the UK typically costs between 8,000 and 15,000 pounds depending on the procedure type and clinic. A gastric sleeve costs approximately 8,000 to 10,000 pounds, while gastric bypass ranges from 10,000 to 15,000 pounds. NHS-funded surgery is available but waiting times can exceed 2 years in many regions.
What happens if I stop taking Ozempic after weight loss?
Research shows that most patients regain a significant proportion of lost weight within 12 months of stopping semaglutide. This is because the medication suppresses appetite and alters gut hormones while you take it. In contrast, bariatric surgery produces permanent anatomical changes. Long-term or indefinite use of GLP-1 therapy is typically needed to maintain results.
Can you combine Ozempic with bariatric surgery?
Emerging evidence supports using GLP-1 medications after bariatric surgery for patients who experience weight regain. Some specialist centres in the UK now prescribe semaglutide or liraglutide post-operatively. Additionally, preoperative GLP-1 use can reduce liver size and improve surgical outcomes. Always discuss combination approaches with your bariatric team.

Related guides